Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences, a biopharmaceutical company that discovers, develops and commercializes therapeutics in areas of unmet medical need, has reported revenues of $1.1bn for the fourth quarter ended 31 December 2010, compared to $2.03bn for the comparable period in 2009.
Subscribe to our email newsletter
Gilead Sciences generated a net income of $629.42m for the fourth quarter 2010, or $0.76 per diluted share, compared to $802.21m, or $0.87 per diluted share, against the same period in 2009.
Gilead Sciences’ income from operations was $829.38m, compared to $1.07m for the comparable period in 2009.
For the full year ended 31 December 2010, revenues were $7.95bnm, compared to $7.01bn during the prior year period.
Income from operations for the full year ended 31 December 2010 was $3.96bn, compared to $3.53bn.
Net income was $2.9bn, or $3.32 per diluted share, compared to $2.64bn, or $2.82 per diluted share.